Vanguard Group Inc Alzamend Neuro, Inc. Transaction History

Vanguard Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.19 - $0.52 $379 - $1,039	-1,999 Reduced 0.1%	2,035,253 $488,000
Q1 2023 May 15, 2023	SELL	$0.37 - $0.71 $205,579 - $394,490	-555,620 Reduced 21.43%	2,037,252 $855,000
Q4 2022 Feb 10, 2023	SELL	$0.53 - $222.0 $796,538 - $334 Million	-1,502,903 Reduced 36.69%	2,592,872 $1.45 Million
Q3 2022 Nov 14, 2022	BUY	$0.88 - $178.5 $3.55 Million - $720 Million	4,035,028 Added 6642.35%	4,095,775 $4.87 Million
Q2 2022 Aug 12, 2022	BUY	$0.82 - $1.2 $49,812 - $72,896	60,747 New	60,747 $53,000

Ticker ALZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,481,800
Market Cap $115M
Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.